STOCK TITAN

Quest Diagnostics Inc - DGX STOCK NEWS

Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.

Quest Diagnostics Incorporated (DGX) provides essential diagnostic insights and testing services across the U.S. healthcare system. This news hub aggregates official press releases, financial updates, and strategic developments from one of America's leading clinical laboratory networks.

Investors and healthcare professionals will find timely updates on earnings reports, partnership announcements, and technological advancements in diagnostic testing. Our curated news feed includes regulatory milestones, service expansions, and innovations leveraging DGX's vast clinical database.

Key updates cover emerging trends in precision diagnostics, laboratory network growth, and healthcare collaborations. Users can track the company's progress in cancer detection, genomic testing, and data-driven health solutions through verified primary sources.

Bookmark this page for direct access to DGX's latest financial performance data, leadership changes, and operational developments. Visit regularly to stay informed about how Quest Diagnostics continues shaping diagnostic medicine through clinical excellence and strategic initiatives.

Rhea-AI Summary

Achievers and Quest Diagnostics have jointly won a Gold award from Brandon Hall Group for the Best Advance in Employee Recognition Program in the Talent Management category. This accolade recognizes their effective workplace strategy in enhancing employee performance through recognition. The collaboration emphasizes Quest's commitment to fostering a culture of appreciation, especially after relaunching RecognitionQuest in 2020. The award ceremony is set for the HCM Excellence Conference from Jan. 31-Feb. 2, 2023, in West Palm Beach, Florida.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
-
Rhea-AI Summary

Takeda has launched the CDPATH™ program, a personalized prognostic tool designed for Crohn's disease patients in the U.S. This tool predicts the risk of developing serious complications within three years using blood tests, and it's offered at no cost to eligible adult patients. The program aims to facilitate shared decision-making between patients and healthcare providers by integrating patient-specific markers with clinical assessments. CDPATH is available through over 2,500 locations nationwide, enhancing patient-centered care for over three million people affected by inflammatory bowel disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
-
Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) is set to present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 4:40 p.m. Eastern Time. CEO-elect Jim Davis and CFO Sam Samad will outline the company's vision and capital strategies. The presentation will be accessible via a live webcast on their investor relations page and archived for later viewing until October 13, 2022. Quest Diagnostics is a premier provider of diagnostic services, serving a significant portion of healthcare professionals and patients in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
conferences
Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) has received emergency use authorization (EUA) from the FDA for its lab-developed test specifically designed to detect Monkeypox virus DNA. This marks the first EUA granted for a commercially available Monkeypox test in the U.S. The Quest Monkeypox PCR test detects DNA from Monkeypox and non-variola Orthopoxvirus in lesion swabs, providing a crucial tool for diagnosis amid the ongoing public health emergency. The test's dual-target capability minimizes false negatives, enhancing reliability. It is now available nationwide, complementing public health laboratory efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
none
-
Rhea-AI Summary

uMETHOD partners with Getlabs to provide at-home lab services for Arizona patients, enhancing accessibility for those with cognitive decline, including mild dementia and Alzheimer's disease. In just one month, mobile service usage quadrupled in the Greater Phoenix area. This partnership aims to improve treatment compliance and patient independence by connecting diagnostics with actionable treatment plans through uMETHOD's RestoreU program. With over 150,000 Arizonans affected by cognitive decline, this initiative addresses a critical healthcare need while collaborating with Sonora Quest Laboratories for efficient sample testing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
none
-
Rhea-AI Summary

Quest Diagnostics has launched a new obstetrics laboratory test panel that incorporates hepatitis C (HCV) screening, following a study indicating that under 41% of pregnant individuals were screened for HCV in 2021. This initiative stems from a Quest Health Trends® study conducted with the CDC, highlighting significant screening gaps, particularly among Medicaid beneficiaries. The new panel aims to close this gap and align with guidelines recommending routine HCV screening during pregnancy, addressing rising HCV infections in the U.S. and potentially improving health outcomes for both mothers and infants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
none
Rhea-AI Summary

Paige partners with Sonora Quest Laboratories to implement a digital pathology workflow in Arizona, enhancing diagnostic processes and patient care. The initiative aims to streamline diagnostics and reduce errors through Paige's advanced AI solutions, including the FDA-approved Paige Prostate Detect. Sonora Quest, part of a leading integrated laboratory system, conducts over 97 million tests annually with a robust test menu. This collaboration is expected to improve the overall healthcare experience and accelerate precision diagnoses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
partnership
-
Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) declared a quarterly cash dividend of $0.66 per share, payable on October 19, 2022. Shareholders of record on October 4, 2022 will receive this dividend, reflecting the company's commitment to returning value to its investors. Quest Diagnostics continues to lead in diagnostic information services, supporting health outcomes with insights derived from its extensive database. This dividend announcement indicates confidence in ongoing business performance and the company's financial health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
dividends
-
Rhea-AI Summary

Quest Diagnostics is launching the "Es Tu Poder" initiative to enhance healthcare access for the Hispanic community in Texas, targeting cities like San Antonio and Houston. The program aims to combat higher disease rates among Hispanics, offering educational tools and resources in collaboration with healthcare organizations. Dr. Romeo Solano emphasizes the initiative's role in addressing health disparities exacerbated by COVID-19, particularly in areas like the Rio Grande Valley. With over 10 million Hispanics in Texas, this project focuses on empowering individuals to take control of their health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
Quest Diagnostics Inc

NYSE:DGX

DGX Rankings

DGX Stock Data

18.18B
111.14M
0.44%
93.75%
2.31%
Diagnostics & Research
Services-medical Laboratories
Link
United States
SECAUCUS